Skechers U.S.A., Inc. has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening IPR2026-00444 on July 24, 2026. As of the initial filing, the PTAB docket reflects the petitioner as Skechers, but practitioners will want to watch the case closely for the full petition, the identification of the challenged patent, the patent owner’s response, and any institution decision that clarifies the scope of the dispute.
At this early stage, the key public takeaway is that a major footwear company has turned to the PTAB to test the validity of a patent that is important enough to warrant administrative review. In an IPR, the petitioner typically challenges one or more claims on anticipation and/or obviousness grounds under 35 U.S.C. §§ 102 and 103, based on patents or printed publications. Those prior-art combinations, and the claim-construction positions Skechers advances, will likely define the strategic importance of the proceeding once the petition papers are fully available.
For patent practitioners, this filing is worth tracking for several reasons. First, design- and utility-related innovation in footwear often sits at the intersection of consumer products, materials, manufacturing methods, and branding-adjacent functionality. PTAB disputes in this space can offer useful guidance on how challengers frame prior art in crowded product categories and how patent owners defend commercial product claims against obviousness attacks.
Second, the case may become a practical study in parallel strategy. If there is related district court litigation, licensing activity, or competitive product conflict behind the petition, the PTAB record could become central to broader enforcement and settlement leverage. Counsel advising product companies will want to monitor whether Skechers seeks a broad merits ruling, a narrower claim-focused challenge, or a timing advantage tied to other proceedings.
Third, institution outcomes in cases involving established consumer brands can be especially instructive on discretionary denial issues, expert support, and real-party-in-interest disclosures. Even before a final written decision, the briefing may provide a useful roadmap for how sophisticated parties present invalidity theories in a commercially sensitive market segment.
Because the currently available docket information is limited, this is a case where updates will matter. The challenged patent number, the named patent owner, and the specific prior-art grounds should all become clearer as the record develops. For now, IPR2026-00444 is one to keep on the watchlist for attorneys handling PTAB strategy, patent assertion risk, and product-company IP disputes.